Likarda has pioneered a groundbreaking platform for hydrogel delivery systems, offering both long- and short-term solutions that can either provide complete immune-protection or degrade gradually. This innovation enables precise localized therapy delivery without the need for immunosuppression, effectively addressing critical gaps in cell therapy. Our CSS Platform significantly enhances therapy efficacy by targeting specific areas, reducing off-target effects, and minimizing the required cell numbers for a therapeutic dose. In essence, Likarda's innovative hydrogel platform revolutionizes cell therapy delivery, addressing challenges in storage, shipping, and targeted delivery while offering scalable, cost-effective solutions.